<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333356</url>
  </required_header>
  <id_info>
    <org_study_id>UC-01610/1617</org_study_id>
    <nct_id>NCT03333356</nct_id>
  </id_info>
  <brief_title>Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)</brief_title>
  <acronym>Bladder-ART</acronym>
  <official_title>Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer: A Randomized Multicentre Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized multicentre study in patients with high-risk MIBC to investigate
      adjuvant radiotherapy after radical cystectomy and pelvic lymph node dissection.

      The objective of the study is to provide evidence that adjuvant radiotherapy improves
      loco-regional control with potential benefits in survival. The study will also evaluate the
      quality of life of patients and the tolerance of the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2018</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pelvic recurrence-free survival (PRFS)</measure>
    <time_frame>3 years</time_frame>
    <description>The PRFS is defined as the delay between randomization and pelvic recurrence or death, whichever occurs first. The pelvic recurrence will be evaluated according to RECIST V1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pelvic recurrence-free survival (PRFS)</measure>
    <time_frame>5 years</time_frame>
    <description>The PRFS is defined as the delay between randomization and pelvic recurrence or death, whichever occurs first. The pelvic recurrence will be evaluated according to RECIST V1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>DFS is defined as the delay between randomization and tumor progression (local, regional, or distant) or death of any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>5 years</time_frame>
    <description>DFS is defined as the delay between randomization and tumor progression (local, regional, or distant) or death of any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>OS is defined as the delay between randomization and death, of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>OS is defined as the delay between randomization and death, of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival (MFS)</measure>
    <time_frame>3 years</time_frame>
    <description>MFS is defined as the delay between randomization, and metastasis (clinical or radiological) or death of any cause whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival (MFS)</measure>
    <time_frame>5 years</time_frame>
    <description>MFS is defined as the delay between randomization, and metastasis (clinical or radiological) or death of any cause whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival (DSS)</measure>
    <time_frame>3 years</time_frame>
    <description>DSS is defined as the delay between randomization and death due to bladder cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival (DSS)</measure>
    <time_frame>5 years</time_frame>
    <description>DSS is defined as the delay between randomization and death due to bladder cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance will be evaluated by toxicity: acute (&lt;6 months after RT) and late (≥6 months after RT), assessed using the NCI CTCAE Version N°4.0</measure>
    <time_frame>5 years</time_frame>
    <description>The tolerance will be evaluated by toxicity: acute (&lt;6 months after RT) and late (≥6 months after RT), assessed using the NCI CTCAE Version N°4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>5 years</time_frame>
    <description>EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>5 years</time_frame>
    <description>The Bladder Cancer Index (BCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by toxicity: acute (&lt;6 months after RT) and late (≥6 months after RT), assessed using the NCI CTCAE Version N°4.0</measure>
    <time_frame>5 years</time_frame>
    <description>The safety will be evaluated by toxicity: acute (&lt;6 months after RT) and late (≥6 months after RT), assessed using the NCI CTCAE Version N°4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Patients With High-risk MIBC</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction /day (duration of RT is 38 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>pelvic radiotherapy</intervention_name>
    <description>adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction /day (duration of RT is 38 days).</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible, the patients must fulfil all of the following inclusion criteria:

          1. Patients with histologically-confirmed muscle-invasive bladder cancer, either with
             pure urothelial carcinomas, or dominant urothelial carcinomas (&gt;50%) combined with
             other histological variants including: micropapillary, epidermoid, or adenocarcinomas,
             are eligible. Patients with small cell variants, pure adenocarcinomas, or pure
             epidermoid carcinomas are not eligible.

          2. Patients with radical cystectomy and pelvic lymph nodes dissection with no macroscopic
             residual disease (R0 and R1).

             Note that only R1 patients without urinary diversion as orthotropic neo-bladder
             replacement are eligible for the study, to limit cystectomy bed radiation induced
             toxicities

          3. Patients with tumours of TNM staging: pN0-2, M0 by imagery, and pT3a, pT3b, pT4a, and
             pT4b, as well as, pTX-pN1-2 are eligible.

          4. Patients having received neo-adjuvant or adjuvant chemotherapy treatment are eligible.
             Randomisation is allowed only if AE due to chemotherapy are ≤grade 2

          5. Patients ≥18 years old.

          6. ECOG performance status ≤2.

          7. Absolute neutrophil count (ANC) ≥1500 cells/mm3

          8. Platelets ≥100000 cells/mm3

          9. Haemoglobin ≥8 g/dL (Note: following a blood transfusion or another intervention if
             required).

         10. Adequate hepatic function: AST (SGOT) and ALT (SGPT) ≤2.5 x ULN; or ≤3.5 x ULN in the
             case of concurrent disease with known etiology and for which a corrective treatment is
             possible.

         11. Adequate renal function: clearance &gt;30 mL/min (MDRD).

         12. Patients of childbearing potential must agree to use a medically acceptable method of
             contraception during the study and for 6 months after the adjuvant radiotherapy.
             Acceptable method of contraception includes: hormonal contraception associated with
             inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal
             associated with inhibition of ovulation (oral, intravaginal, transdermal),
             intrauterine devices, sexual abstinence, bilateral tubal ligation, vasectomy, for
             female: partner who have had a vasectomy, for male: partner who is not of childbearing
             potential. Women must have a negative urine or serum pregnancy test within 14 days
             prior to randomization.

         13. Patients having provided written informed consent prior to any study-related
             procedures.

         14. Patients affiliated to the social security scheme.

         15. Patients willing and able to comply with the scheduled visits, treatment plan,
             laboratory tests, and other study procedures indicated in the protocol.

        Exclusion Criteria:

        Patient must not be enrolled if he/she fulfils any of the following non-inclusion criteria:

          1. Patients with R1 resection and with orthotropic neo-bladder reconstruction as urinary
             diversion are not eligible.

          2. Patients with clinical or radiological evidence of metastases or N3 staged bladder
             cancer are not eligible.

          3. Prior invasive solid tumours or haematological malignancies (except skin basal cell
             carcinoma, in situ epithelioma of the cervix, or prostate cancer [incidentally
             discovered during cystoprostatetectomy and pelvic lymph node dissection)] and with a
             good prognosis [T stage &lt;pT3b and/or Gleason &lt;8 and pN- and/or post-operative PSA &lt;0.1
             nanogramm/mL]), unless disease free for a minimum of three years prior to inclusion.

          4. Prior pelvic radiotherapy.

          5. Patients with active inflammatory bowel disease.

          6. Patients who required surgical treatment for bowel obstruction before bladder cancer
             diagnosis or after cystectomy.

          7. Prior chemotherapy for other malignant diseases, except for neoadjuvant pre-cystectomy
             chemotherapy which is permitted.

          8. Patients with the following severe acute co-morbidity are not eligible:

               -  Unstable angina or congestive heart failure that required hospitalization in the
                  6 months before randomisation.

               -  Transmural myocardial infarction in the 6 months prior to randomisation.

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at
                  randomization.

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy at the time of inclusion.

               -  Severe hepatic disease: Child-Pugh Class B or C hepatic disease.

               -  Known acquired immune deficiency syndrome (AIDS); the study treatment could
                  impact blood count.

          9. Patients with any other disease or illness which requires hospitalization or is
             incompatible with the study treatment are not eligible.

         10. Patients unable to comply with study obligations for geographic, social, or physical
             reasons, or who are unable to understand the purpose and procedures of the study.

         11. Patients enrolled in another therapeutic study within 30 days prior of randomisation.

         12. Pregnant or breast feeding mothers.

         13. Person deprived of their liberty or under protective custody or guardianship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul SARGOS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stéphane LARRE, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Robert Debré</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra PELISSIER</last_name>
    <phone>+ 33 1 44 23 55 68</phone>
    <email>s-pelissier@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique de L'Europe</name>
      <address>
        <city>Amiens</city>
        <zip>80090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel GOZY, MD</last_name>
      <phone>+33 3 60 12 76 78</phone>
      <email>michelgozy@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Générale d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne DONEUX, MD</last_name>
      <phone>+33 4 50 63 69 89</phone>
      <email>adoneux@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul SARGOS, MD</last_name>
      <phone>+ 33 5 56 33 33 76</phone>
      <email>P.Sargos@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur Cfro</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ali HASBINI, MD</last_name>
      <phone>+33 2 98 31 32 00</phone>
      <email>alihasbini@oncologie-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yazid BELKACEMI, Prof</last_name>
      <phone>+33 1 49 81 45 22</phone>
      <email>yazid.belkacemi@hmn.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Etienne MARTIN, MD</last_name>
      <phone>+33 3 80 73 75 18</phone>
      <email>emartin@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier VERRY, MD</last_name>
      <phone>+33 4 76 76 54 35</phone>
      <email>cverry@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David PASQUIER, MD</last_name>
      <phone>+33 3 20 29 51 44</phone>
      <email>d-pasquier@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre CLAVERE, Prof</last_name>
      <phone>+33 5 55 05 62 69</phone>
      <email>pierre.clavere@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale POMMIER, MD</last_name>
      <phone>+33 4 78 78 51 66</phone>
      <email>pascal.pommier@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier MURACCIOLE, MD</last_name>
      <email>xavier.muracciole@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Regional Du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David AZRIA, Prof</last_name>
      <phone>+33 4 67 61 85 79</phone>
      <email>david.azria@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe HENNEQUIN, Prof</last_name>
      <phone>+33 1 42 49 90 24</phone>
      <email>christophe.hennequin2@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine DURDUX, Prof</last_name>
      <phone>+33 1 56 09 34 02</phone>
      <email>catherine.durdux@.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hu Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc SIMON, MD</last_name>
      <phone>+33 1 42 17 81 60</phone>
      <email>jean-marc.simon@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier CHAPET, Prof</last_name>
      <phone>+33 4 78 86 42 51</phone>
      <email>olivier.chapet@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renaud DE CREVOISIER, MD</last_name>
      <phone>+33 2 99 25 30 31</phone>
      <email>r.de-crevoisier@rennes.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chp Saint-Gregoire</name>
      <address>
        <city>Saint Gregoire</city>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier ARTIGNAN</last_name>
      <phone>+33 2 90 09 44 64</phone>
      <email>xartignan@vivalto-sante.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO - site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane SUPIOT, MD</last_name>
      <phone>+33 2 40 67 99 13</phone>
      <email>stephane.supiot@ico.unicacner.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE, Prof</last_name>
      <phone>+33 4 77 91 71 04</phone>
      <email>nicolas.magne@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre GRAFF-CAILLEAUD, MD</last_name>
      <phone>+33 5 31 15 54 30</phone>
      <email>graff-cailleaud.pierre@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Igor LATORZEFF, MD</last_name>
      <phone>+33 5 67 20 44 00</phone>
      <email>i.latorzeff@clinique-pasteur.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre BLANCHARD, MD</last_name>
      <phone>+33 1 42 11 41 25</phone>
      <email>Pierre.BLANCHARD@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

